

# Dermal Laboratories Ltd

## Methodological note for HCP/ORDM/HCO disclosure 2025

Data year: 2025

Year of publication: 2026

**Contents**

- 1 **Definitions** ..... 2
  - 1.1 Recipients ..... 2
  - 1.2 Kind of ToVs ..... 2
- 2 **Disclosure's Scope** ..... 2
  - 2.1 Products concerned ..... 2
  - 2.2 Company concerned ..... 2
  - 2.3 Excluded ToVs ..... 2
  - 2.4 ToVs date ..... 2
  - 2.5 Direct ToVs ..... 3
  - 2.6 Indirect ToVs ..... 3
  - 2.7 Non-monetary ToVs ..... 3
  - 2.8 ToVs in case of partial attendances or cancellation and refund ..... 3
  - 2.9 Cross-border activities ..... 3
  - 2.10 R&D ..... 3
  - 2.11 Voluntary disclosure ..... 3
- 3 **Specific considerations** ..... 3
  - 3.1 Country unique identifier ..... 3
  - 3.2 Self-incorporated HCP ..... 3
  - 3.3 Multi-year agreements ..... 3
  - 3.4 Country specificities ..... 3
  - 3.5 Quality Checks ..... 4
- 4 **Data protection legal basis** ..... 4
  - 4.1 Consent collection ..... 4
  - 4.2 Legitimate interests ..... 4
- 5 **Form of disclosure** ..... 4
  - 5.1 Date of publication ..... 4

5.2	Disclosure platform .....	5
5.3	Disclosure language.....	5
6	<b>Disclosure financial data</b> .....	5
6.1	Currency .....	5
6.2	VAT included or excluded.....	5
6.3	Calculation rules.....	5
7	<b>Additional Information</b> .....	5

# 1 Definitions

## 1.1 Recipients

Individual healthcare professionals (HCPs) including secondary and primary care medical practitioners, nurses and trainers.

Secondary and Primary Care Healthcare Organisations (HCOs), including organisers of medical education events for individual or associations of healthcare professionals.

## 1.2 Kind of ToVs

A number of payments have been made by Dermal during 2025 with regards to medical education events, which include the following:

Sponsorship agreements for Healthcare Organisations relating to the organisation of educational events.

Contributions towards the costs of attending educational events, including Registration Fees, Travel and Accommodation.

Payments for Consultancy Fees, such as Speaker Fees and related expenses at educational events and for Company Medical Advisor and new product development advice.

Aggregate fees for payments for clinical trial activities.

# 2 Disclosure's Scope

## 2.1 Products concerned

Dermal Laboratories Ltd has a range of products available in the UK, including licensed medicines (POM, P and GSL) and Medical Devices. These products may be prescribed on the NHS, and all apart from the two prescription only medicines, may also be purchased from a pharmacy.

## 2.2 Company concerned

These payments have been made by Dermal Laboratories Ltd to UK HCPs and HCOs.

## 2.3 Excluded ToVs

No payments regarding Joint Working have been made by Dermal in 2025.

## 2.4 ToVs date

This disclosure covers payments made to HCPs and HCOs during the calendar year 2025.

Each column contains data relating to the type of payment made. Payments to named individual HCPs have been provided as an annual total for each payment type. Where consent is not

received for named disclosure, this is provided as an aggregate total. Payments made to HCOs are listed by type on each occasion when made through the year.

#### **2.5 Direct ToVs**

Payments towards the registration, travel expenses or consultancy fee for speaking or chairing medical educational meetings.

#### **2.6 Indirect ToVs**

Third party event organisers for sponsoring medical educational meetings.

#### **2.7 Non-monetary ToVs**

Not applicable

#### **2.8 ToVs in case of partial attendances or cancellation and refund**

Not applicable

#### **2.9 Cross-border activities**

Not applicable

#### **2.10 R&D**

Payments for Company Medical Advisor and new product development advice.  
Payments for clinical trial activities (aggregate fees only are required to be submitted and therefore consent to submit from each individual investigator is not necessary).

#### **2.11 Voluntary disclosure**

Not applicable

### **3 Specific considerations**

#### **3.1 Country unique identifier**

Not applicable

#### **3.2 Self-incorporated HCP**

Not applicable

#### **3.3 Multi-year agreements**

Not applicable

#### **3.4 Country specificities**

Not applicable

### **3.5 Quality Checks**

For the year of 2025, the appropriate HCPs/HCOs were required, in liaison with Dermal, to sub-divide into the specified categories any relevant payments made directly or indirectly to them in relation to the activity/service involved. For example, in the case of HCPs attending events/conferences, their registration fees were itemised separately from any agreed travel and accommodation payments, and for HCPs providing a consultancy service separate accounts were agreed for professional fees and agreed related expenses. The purpose(s) of any consultancy service was set out in a suitable written agreement including an obligation for the consultant to declare they are a consultant for Dermal whenever they write or speak in public about any issue relating to Dermal. These agreements also made it clear that Dermal is prohibited from incentivising or rewarding HCPs for their past, present or future use or support of a medicine or from influencing the outcome of any clinical trial(s) or for any other improper purpose.

## **4 Data protection legal basis**

### **4.1 Consent collection**

Informed consent was asked for when the contribution towards costs, or fee for services or consultancy was commissioned by Dermal, and a written agreement was signed. Whilst 'open' disclosure is encouraged in the spirit of transparency, individuals were free to decide whether or not they wish to give their consent to named disclosure.

After the end of 2025, Dermal wrote to each HCP/HCO in receipt of a payment during 2025, with a summary of the data that was due to be submitted, either by name, or where 'open' disclosure was not consented, as an anonymous payment for publication purposes. All HCOs were notified at this time that their payments will be publicly declared, as required by the 2024 edition of the ABPI Code of Practice.

In March, this data was securely uploaded onto a web-based platform, along with data from other companies. A specialist data management company consolidates and reconciles the records from each company to ensure the data are complete and the database has accurate search functionality. During this process, HCPs/HCOs have the opportunity to raise with Dermal any queries regarding the data. At the end of June the finalised database is published via the ABPI website ([www.abpi.co.uk](http://www.abpi.co.uk)).

The information disclosed will remain publicly accessible for at least three years from the date of disclosure, and each pharmaceutical company will be required to keep their detailed records of such payments for at least 5 years after the year to which they relate.

### **4.2 Legitimate interests**

Not applicable

## **5 Form of disclosure**

### **5.1 Date of publication**

17/03/2026

## **5.2 Disclosure platform**

Disclosure UK – [www.disclosureuk.org.uk](http://www.disclosureuk.org.uk)

## **5.3 Disclosure language**

English

# **6 Disclosure financial data**

## **6.1 Currency**

GBP

## **6.2 VAT included or excluded**

Where appropriate, VAT is not included within the listed payment quantity.

## **6.3 Calculation rules**

Not applicable

# **7 Additional Information**

Personal information is managed in accordance with the requirements of the General Data Protection Regulation (Regulation (EU) 2016/679) and the Data Protection Act 1998.